You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
McKinsey
Colorcon
Johnson and Johnson
Dow

Last Updated: October 2, 2023

PRISTIQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Pristiq patents expire, and when can generic versions of Pristiq launch?

Pristiq is a drug marketed by Pf Prism Cv and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has twenty-two patent family members in sixteen countries.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Drug patent expirations by year for PRISTIQ
Drug Prices for PRISTIQ

See drug prices for PRISTIQ

Drug Sales Revenue Trends for PRISTIQ

See drug sales revenues for PRISTIQ

Recent Clinical Trials for PRISTIQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Mental Health (NIMH)Phase 4
David SteffensPhase 4
Korea Cancer Center HospitalPhase 4

See all PRISTIQ clinical trials

Paragraph IV (Patent) Challenges for PRISTIQ
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PRISTIQ Extended-release Tablets desvenlafaxine succinate 25 mg 021992 1 2015-05-08
PRISTIQ Extended-release Tablets desvenlafaxine succinate 50 mg and 100 mg 021992 12 2012-02-29

US Patents and Regulatory Information for PRISTIQ

PRISTIQ is protected by one US patents.

Patents protecting PRISTIQ

Derivatives of venlafaxine and methods of preparing and using the same
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PRISTIQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PRISTIQ

See the table below for patents covering PRISTIQ around the world.

Country Patent Number Title Estimated Expiration
New Zealand 514612 Derivatives of venlafaxine and methods of preparing and using the same ⤷  Try a Trial
Mexico PA03007043 NUEVA SAL DE SUCCINATO DE O-DESMETIL-VENLAFAXINA. (NOVEL SUCCINATE SALT OF O-DESMETHYL-VENLAFAXINE.) ⤷  Try a Trial
Poland 212943 ⤷  Try a Trial
Cyprus 1106952 ⤷  Try a Trial
European Patent Office 2319826 ⤷  Try a Trial
Eurasian Patent Organization 200300873 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Colorcon
Moodys
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.